Archer Investment Corporation’s Alnylam Pharmaceuticals ALNY Stock Holding History

Archer Investment Corporation’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.31K	Hold	10	–	–	﹤0.01%	992
2025 Q4	$3.98K	Hold	10	–	–	﹤0.01%	902
2025 Q3	$4.56K	Hold	10	–	–	﹤0.01%	885
2025 Q2	$3.26K	Buy	+10	New	+$2.77K	﹤0.01%	905
2024 Q1	–	Sell	-200	Closed	-$38.3K	–	1046
2023 Q4	$38.3K	Hold	200	–	–	0.01%	440
2023 Q3	$35.4K	Hold	200	–	–	0.01%	427
2023 Q2	$38K	Hold	200	–	–	0.01%	414
2023 Q1	$40.1K	Buy	+200	New	+$42K	0.01%	411

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Archer Investment Corporation's ALNY Position: Q1 2026 in Review

Archer Investment Corporation held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 10 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #992.

Archer Investment Corporation first reported a position in ALNY in Q1 2023 and has held it in 8 quarters since. The position peaked at $40.1K in Q1 2023. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Archer Investment Corporation held 10 shares of Alnylam Pharmaceuticals worth $3.31K as of Q1 2026.
Archer Investment Corporation left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Archer Investment Corporation's portfolio in Q1 2026, its #992 holding.
Archer Investment Corporation first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
Archer Investment Corporation's Alnylam Pharmaceuticals position peaked at $40.1K in Q1 2023.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Archer Investment Corporation's 13F filing for Q1 2026, filed 4 May 2026.